Minoryx Therapeutics, a Mataró, Barcelona, Spain-based company focused on finding novel treatments for life threatening rare diseases, raised €1.5m in its first funding.
Backers included Caixa Capital Risc and Inveready, via Inveready Biotech II.
The company intends to use the capital to advance the development of treatments for life threatening rare diseases, complete preclinical studies required to begin human clinical studies in 2015.
Founded in 2011 and led by Dr. Marc Martinell, Dr. Joan Aymamí and Dr. Xavier Barril, Minoryx prioritizes pediatric diseases and is currently focused on neurometabolic diseases of genetic origin.
The company develops a new generation of small molecule drugs named pharmacological chaperones, which promise to treat genetic diseases affecting the central nervous system. Minoryx is located at Parc TecnoCampus Mataró-Maresme.
FinSMEs
04/04/2013